clec12b: a potential drug target and biomarker (G387837)

Target Name: CLEC12B

NCBI ID: G387837

CLEC12B

clec12b: a potential drug target and biomarker

Introduction

CLEC12B, also known as C-type lectin domain family 12 member B, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the Clec12 family of structurally similar lectins, which are characterized by the presence of a C-type lectin domain and a variable ending. Clec12B is known to be involved in various cellular processes, including cell adhesion, migration, and signaling pathways.

Drug targeting

CLEC12B has been identified as a potential drug target due to its unique structure and its involvement in several cellular processes. The C-type lectin domain of Clec12B is known to be involved in the formation of inclusion domains, which are regions that can interact with other proteins and molecules. This domain is also known to play a role in the formation of aggregates, which can be harmful to cells.

One of the potential drug targets for Clec12B is its role in cell adhesion. Clec12B is known to be involved in the formation of tight junctions, which are a type of cell-cell adhesion that is critical for maintaining tissue structure and function. Additionally, Clec12B is involved in the formation of cadherins, which are a type of transmembrane protein that is involved in cell-cell adhesion.

Another potential drug target for Clec12B is its role in cell migration. Clec12B is known to be involved in the regulation of cell migration, which is critical for the development and maintenance of tissues and organs. Additionally, Clec12B is involved in the regulation of cell survival , which is critical for the regulation of cellular processes that are necessary for cell survival.

Biomarker

CLEC12B has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is due to its involvement in various cellular processes that are affected in these diseases. For example, Clec12B is known to be involved in the regulation of cell adhesion, which is critical for the development and progression of cancer. Additionally, Clec12B is involved in the regulation of cell survival, which is critical for the regulation of cellular processes that are necessary for cell survival in neurodegenerative diseases.

Conclusion

In conclusion, Clec12B is a protein that is involved in various cellular processes throughout the body. It is a potential drug target due to its unique structure and its involvement in several cellular processes that are important for human health. Additionally, Clec12B has been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the role of Clec12B in these diseases and to develop effective treatments.

Protein Name: C-type Lectin Domain Family 12 Member B

Functions: Inhibitory receptor postulated to negatively regulate immune and non-immune functions (PubMed:17562706, PubMed:34310951). Upon phosphorylation, recruits SH2 domain-containing PTPN6 and PTPN11 phosphatases to its ITIM motif and antagonizes activation signals (PubMed:17562706, PubMed:34310951). Although it inhibits KLRK1/NKG2D-mediated signaling, it does not bind known ligands of KLRK1/NKG2D and therefore is not its inhibitory counterpart (PubMed:17562706). May limit activation of myeloid cell subsets in response to infection or tissue inflammation (PubMed:17562706). May protect target cells against natural killer cell-mediated lysis (PubMed:17562706). May negatively regulate cell cycle and differentiation of melanocytes via inactivation of STAT3 (PubMed:34310951)

The "CLEC12B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC12B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets